GSK's Nuvalent Deal Makes Strategic Sense -- Market Talk

Dow Jones

06/09

1349 GMT - GSK's $10.6 billion acquisition of Nuvalent seems to make strategic sense, even if it is bigger than the deals the U.K. drugmaker has targeted in the past, Bernstein analysts say in a research note. The company expects Nuvalent to be different from its last big oncology acquisition, a $5 billion deal for Tesaro back in 2019, the analysts say. The Tesaro deal hasn't created value, but GSK will take measures to mitigate the dilution on profitability from the deal this time around, according to Bernstein. GSK hopes its broad geographic reach and the better tolerability profile of Nuvalent's lung-cancer drugs compared to available therapies can make the deal work, the analysts say. Shares in GSK fall 1.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 09, 2026 09:49 ET (13:49 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2642493507"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642493507\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642493507?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 21:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642493507","market":"sg","top_or_hot":-1,"title":"GSK's Nuvalent Deal Makes Strategic Sense -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1349 GMT - GSK's $10.6 billion acquisition of Nuvalent seems to make strategic sense, even if it is bigger than the deals the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker has targeted in the past, Bernstein analysts say in a research note. The company expects Nuvalent to be different from its last big oncology acquisition, a $5 billion deal for Tesaro back in 2019, the analysts say. The Tesaro deal hasn't created value, but GSK will take measures to mitigate the dilution on profitability from the deal this time around, according to Bernstein. GSK hopes its broad geographic reach and the better tolerability profile of Nuvalent's lung-cancer drugs compared to available therapies can make the deal work, the analysts say. Shares in GSK fall 1.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 09:49 ET (13:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK's Nuvalent Deal Makes Strategic Sense -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK's Nuvalent Deal Makes Strategic Sense -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 21:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1349 GMT - GSK's $10.6 billion acquisition of Nuvalent seems to make strategic sense, even if it is bigger than the deals the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker has targeted in the past, Bernstein analysts say in a research note. The company expects Nuvalent to be different from its last big oncology acquisition, a $5 billion deal for Tesaro back in 2019, the analysts say. The Tesaro deal hasn't created value, but GSK will take measures to mitigate the dilution on profitability from the deal this time around, according to Bernstein. GSK hopes its broad geographic reach and the better tolerability profile of Nuvalent's lung-cancer drugs compared to available therapies can make the deal work, the analysts say. Shares in GSK fall 1.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 09:49 ET (13:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642493507","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642493507","pubTimestamp":1781012940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1349 GMT - GSK's $10.6 billion acquisition of Nuvalent seems to make strategic sense, even if it is bigger than the deals the U.K. drugmaker has targeted in the past, Bernstein analysts say in a research note. The company expects Nuvalent to be different from its last big oncology acquisition, a $5 billion deal for Tesaro back in 2019, the analysts say. The Tesaro deal hasn't created value, but GSK will take measures to mitigate the dilution on profitability from the deal this time around, according to Bernstein. GSK hopes its broad geographic reach and the better tolerability profile of Nuvalent's lung-cancer drugs compared to available therapies can make the deal work, the analysts say. Shares in GSK fall 1.3%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","BK4588":"碎股","BK4539":"次新股","BK4585":"ETF&股票定投概念","NUVL":"Nuvalent, Inc.","GSK":"葛兰素史克","GSKH":"GSK plc ADRhedged","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"葛兰素史克的Nuvalent交易具有战略意义——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"NUVL":1.5,"GSK":1.5,"GSK.UK":0.6},"content_text":"1349 GMT - GSK's $10.6 billion acquisition of Nuvalent seems to make strategic sense, even if it is bigger than the deals the U.K. drugmaker has targeted in the past, Bernstein analysts say in a research note. The company expects Nuvalent to be different from its last big oncology acquisition, a $5 billion deal for Tesaro back in 2019, the analysts say. The Tesaro deal hasn't created value, but GSK will take measures to mitigate the dilution on profitability from the deal this time around, according to Bernstein. GSK hopes its broad geographic reach and the better tolerability profile of Nuvalent's lung-cancer drugs compared to available therapies can make the deal work, the analysts say. Shares in GSK fall 1.3%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 09:49 ET (13:49 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}